PF-03446962
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for PF-03446962, covering 2015-06-29 to 2023-08-04. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma [Phase 2]